LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Protagonist Therapeutics, Inc. Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showowing Durable Hematocrit Control CI
Protagonist Therapeutics Insider Sold Shares Worth $1,231,650, According to a Recent SEC Filing MT
Protagonist Therapeutics Insider Sold Shares Worth $280,000, According to a Recent SEC Filing MT
Protagonist Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Protagonist Therapeutics Insider Sold Shares Worth $707,750, According to a Recent SEC Filing MT
Protagonist Therapeutics, Inc. Provides Update on Verify Patient Enrollment and Timing of Top-Line Data CI
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda CI
Protagonist Therapeutics' Potential Plaque Psoriasis Drug Shows High Skin Clearance Rates in Phase 2B Study MT
Protagonist Therapeutics, Inc. Announces Late-Breaking Presentation At the American Academy of Dermatology 2024 Annual Meeting with Positive Results from the Phase 2B Frontier 2 Long-Term Extension Study Evaluating JNJ-2113, the First and Only Investigational Targeted Oral Peptide Designed to Block the IL-23 Receptor, for Adult Patients with Moderate-To-Severe Plaque Psoriasis CI
Protagonist Therapeutics Insider Sold Shares Worth $948,600, According to a Recent SEC Filing MT
Protagonist Therapeutics Insider Sold Shares Worth $406,637, According to a Recent SEC Filing MT
Protagonist Therapeutics Insider Sold Shares Worth $764,365, According to a Recent SEC Filing MT
JPMorgan Adjusts Price Target on Protagonist Therapeutics to $37 From $34, Maintains Overweight Rating MT
Protagonist Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Protagonist Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Protagonist Therapeutics Shares Rise 5.6% on Licensing Deal With Takeda DJ
Transcript : Protagonist Therapeutics, Inc. - Special Call
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset CI
Transcript : Protagonist Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 09:45 AM
Protagonist Therapeutics Insider Sold Shares Worth $1,506,000, According to a Recent SEC Filing MT
Protagonist Therapeutics Earns $10 Million Milestone Payment in Ulcerative Colitis Trial MT
Protagonist Therapeutics, Inc. Announces $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis CI
Protagonist Therapeutics, Inc. Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-To-Head Comparisons with Deucravacitinib CI
Protagonist Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Protagonist Therapeutics, Inc. Announces Achievement of $50 Million Milestone Event After Third Patient is Dosed in Phase 3 Study of JNJ-2113 in Moderate-to-Severe Psoriasis CI
Chart Protagonist Therapeutics, Inc.
More charts
Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. The Company’s Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned investigational orally delivered gut-restricted alpha 4 beta 7 (α4β7) specific integrin antagonist for inflammatory bowel disease (IBD).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
33.39 USD
Average target price
43.83 USD
Spread / Average Target
+31.28%
Consensus
  1. Stock Market
  2. Equities
  3. PTGX Stock
  4. News Protagonist Therapeutics, Inc.
  5. Protagonist Therapeutics Insider Sold Shares Worth $707,750, According to a Recent SEC Filing